



Sickle Cell Anemia: Variants in the *CYP2D6*, *CAT*, and *SLC14A1* Genes Are Associated With Improved Hydroxyurea Response

OPEN ACCESS

Edited by:

George P. Patrinos,
University of Patras, Greece

Reviewed by:

Vasiliki Chondrou,
Hellenic Open University, Greece
Kariofyllis Karamperis,
University of Patras, Greece

*Correspondence:

Marilda Souza Goncalves
mari@bahia.fiocruz.br

Specialty section:

This article was submitted to
Pharmacogenetics
and Pharmacogenomics,
a section of the journal
Frontiers in Pharmacology

Received: 17 April 2020

Accepted: 18 August 2020

Published: 09 September 2020

Citation:

Yahouédéhou SCMA, Neres JSdS,
da Guarda CC, Carvalho SP,
Santiago RP, Figueiredo CVB,
Fiuza LM, Ndidi US, de Oliveira RM,
Fonseca CA, Nascimento VML,
Rocha LC, Adanho CSA,
da Rocha TSC, Adorno EV and
Goncalves MS (2020) Sickle Cell
Anemia: Variants in the *CYP2D6*, *CAT*,
and *SLC14A1* Genes Are
Associated With Improved
Hydroxyurea Response.
Front. Pharmacol. 11:553064.
doi: 10.3389/fphar.2020.553064

Sètondji Cocou Modeste Alexandre Yahouédéhou^{1,2}, Joelma Santana dos Santos Neres¹,
Caroline Conceição da Guarda^{1,2}, Suellen Pinheiro Carvalho^{1,2}, Rayra Pereira Santiago^{1,2},
Camylla Vilas Boas Figueiredo^{1,2}, Luciana Magalhães Fiuza^{1,2}, Uche Samuel Ndidi³,
Rodrigo Mota de Oliveira^{1,2}, Cleverton Alves Fonseca², Valma Maria Lopes Nascimento⁴,
Larissa Carneiro Rocha⁴, Corynne Stéphanie Ahouéfa Adanho¹,
Tiago Santos Carvalho da Rocha¹, Elisângela Vitória Adorno²
and Marilda Souza Goncalves^{1,2*}

¹ Laboratório de Investigação em Genética e Hematologia Translacional, Instituto Gonçalo Moniz, Salvador, Brazil,

² Laboratório de Pesquisa em Anemia, Departamento de Análises Clínicas, Faculdade de Farmácia, Universidade Federal da Bahia, Salvador, Brazil, ³ Department of Biochemistry, Ahmadu Bello University, Zaria, Nigeria, ⁴ Ambulatório, Fundação de Hematologia e Hemoterapia da Bahia, Salvador, Brazil

Differences in hydroxyurea response in sickle cell anemia may arise due to a series of factors with genetic factors appearing to be predominant. This study aims to investigate the effects of single nucleotide polymorphisms in genes encoding drug-metabolizing enzymes and solute carriers on hydroxyurea response, in patients with sickle cell anemia. For that purpose, a total number of 90 patients with sickle cell anemia were recruited, 45 were undergoing hydroxyurea treatment, while 45 were not under the treatment. Association analyses were performed between *CYP3A4* (rs2740574), *CYP2D6* (rs3892097), *CAT* (rs7943316 and rs1001179), and *SLC14A1* (rs2298720) variants and laboratory parameters. According to our findings, patients with hydroxyurea treatment demonstrated higher HbF levels and a significant improvement in hemolytic, hepatic, inflammatory, and lipid parameters in comparison to those without the treatment. We also found significant associations between the *CYP2D6* (rs3892097), *CAT* (rs7943316 and rs1001179), and *SLC14A1* (rs2298720) variants and an improvement of the therapeutic effects, specifically the hemolytic, hepatic, inflammatory, lipid, and renal parameters. In conclusion, our results highlight the importance of the investigated variants, and their strong association with hydroxyurea efficacy in patients with sickle cell anemia, which may be considered in the future as genetic markers.

Keywords: sickle cell anemia, hydroxyurea, *CYP2D6*, *CYP3A4*, *CAT*, *SLC14A1*, laboratory parameters

INTRODUCTION

Hydroxyurea (HU) is an antineoplastic drug primarily used to treat patients with myeloproliferative syndromes (Bandeira et al., 2004; Kovacic, 2011). In addition to its antimetabolite effects, studies have also demonstrated an anti-sickling action. Accordingly, HU was approved by the U.S. Food and Drug Administration for the treatment of patients with sickle cell anemia (SCA) in the context of a severe clinical profile (King, 2003; Huang et al., 2006; Koliopoulou et al., 2017). Reports have demonstrated that HU treatment leads to increases in fetal hemoglobin (HbF), mean corpuscular hemoglobin (MCH) and mean corpuscular volume (MCV), as well as decreases in white blood cell (WBC), platelet and reticulocyte counts. Furthermore, HU is also associated with reduced adhesion molecule expression and greater nitric oxide (NO) bioavailability (King, 2003; Rees et al., 2010; Sassi et al., 2010; Silva-Pinto et al., 2013; Yahouédéhou et al., 2019). Clinically, patients with SCA undergoing HU treatment present a lower incidence of painful crises, rates of hospitalization, acute chest syndrome episodes, blood transfusion and mortality (King, 2003; Rees et al., 2010; Sassi et al., 2010; Silva-Pinto et al., 2013). Despite these beneficial effects, studies have also demonstrated inter-individual variations in the therapeutic response to HU (Ware et al., 2002; King, 2003; Ma et al., 2007; Ware, 2010). This may be attributed to therapy adherence, or socioeconomic, environmental, physiological and genetic factors. Nonetheless, genetic factors have been highlighted as one of the most important determinants of variation in HU therapeutic response (Gravia et al., 2014; Yahouédéhou et al., 2018a).

Polymorphisms in genes encoding drug-metabolizing enzymes (DME) and solute carriers may alter the bioavailability of drugs and metabolism, thereby influencing efficiency and toxicity (Sheng et al., 2014). Accordingly, we recently conducted a review of the literature focused on genome-wide association studies that investigated genetic biomarkers effects on HU response and studies that investigated HU metabolism (Yahouédéhou et al., 2018a). Evidence showed the involvement of enzymes of the CYP450 family and catalase in HU metabolism, as well as the association between the urea transporter-B (UTB) and HU response in erythroid cells.

In the present study, two isoenzymes of the CYP450 family (CYP3A4 and CYP2D6) were selected, due to their importance in the metabolism of various endo- or xenobiotics. It was reported that CYP3A4 isoenzyme is more abundant in the liver, can metabolize 50% of commercially available drugs and has substrates such as steroid hormones, analgesics and antihistamines, as well as antitumor and immunosuppressive agents (Božina et al., 2009). The CYP3A4 isoenzyme is encoded by the polymorphic respective gene, located on chromosome 7 (7q22.1) and in particular, the CYP3A4 -392A>G (rs2740574) is associated with increased gene transcription and CYP3A4 activity (Jin et al., 2005; Božina et al., 2009; Bhatnagar et al., 2010; Maruf et al., 2012; He et al., 2014). As its homolog, CYP2D6 isoenzyme is also more expressed in the liver and encoded by the CYP2D6 gene located on chromosome 22 (22q13.2). This isoenzyme metabolizes approximately 25% of

all known drugs, including antidepressants, antiarrhythmics, analgesics and anticancer agents. Moreover, studies showed the association of the polymorphism CYP2D6 1934G>A (rs3892097) with reduced CYP2D6 activity and increased intoxication risk, as well as side effects, following exposure to xenobiotics (Božina et al., 2009; Sayed and Imam, 2012).

In addition to these isoenzymes, we also selected catalase and UTB. Catalase is an important endogen antioxidant enzyme, involved in neutralization pathways of reactive oxygen species. Evidence has shown that it is most abundant in the liver, kidney, and erythrocytes (Forsberg et al., 2001; Babusikova et al., 2013; Liu et al., 2015). Moreover, it was demonstrated that catalase can convert HU into nitrite/nitrate, and HU toxicity *in vivo* is dependent on its activity (Huang et al., 2004; King, 2005; Juul et al., 2010). This enzyme is encoded by the CAT gene, located on chromosome 11 (11p13.31) and, according to the latest updates, -21A>T (rs7943316), and -262C>T (rs1001179) variants where are located in the promoter region of this gene, have been associated with reduced transcription and enzyme activity (Perianayagam et al., 2007; Liu et al., 2015). The UTB, also named Solute Carrier Family 14 Member 1 (SLC14A1), is a family of urea transporters important to the regulation of urine concentration (Garcia-Closas et al., 2011; Stewart, 2011; Matsuda et al., 2015; Ebbinghaus et al., 2017). This protein, encoded by the SLC14A1 gene, located on chromosome 18 (18q12.3), is widely expressed on the plasma membranes of red blood cells and poorly expressed in endothelial cells of the descending rectum vessel in the kidney, brain, ear, testis, intestine, and urinary bladder (Sands, 2002; Garcia-Closas et al., 2011; Rafnar et al., 2011; Ebbinghaus et al., 2017). It is known that several molecules (methylurea, formamide, methylformamide, acetamide, and acrylamide) may transit, rapidly, and passively, *via* channel proteins such as UTB (Esteva-Font et al., 2015; Hou et al., 2017). Interestingly, a study performed in patients with SCA demonstrated an association between the rs12605147 and rs2298720 variants in the SLC14A1 gene and variations in HU pharmacokinetics (Ware et al., 2011).

Based on this evidence, we conducted the present study, which aimed to investigate, in SCA patients undergoing HU treatment, possible associations between laboratory parameters and the rs2740574, rs3892097, rs7943316, rs1001179, rs2298720 variants, linked to alterations in gene expression and/or enzyme activity.

MATERIALS AND METHODS

Subjects and Ethical Aspects

The present cross-sectional study included patients with SCA (HbSS), all seen at the outpatient clinic of the Hematology and Hemotherapy Foundation of Bahia (HEMOBA), located in Salvador, Brazil. Forty-five (45) patients on HU treatment (HU⁺), as well as 45 who were not using this treatment (HU⁻), were enrolled. Twenty-two (48.89%) HU⁺ patients were female compared to 20 (44.44%) in the HU⁻ group. The median age of

the HU⁺ group was 15 years (range: 9–22 years), versus 15.5 years (range: 7–21 years) in the HU⁻ group. All patients reported regular use of folic acid and were in steady-state, defined as the absence of acute crisis and no use of blood transfusion in the three months prior to blood collection. HU dosage ranged between 10.5 and 27.6 mg/kg/day (median: 16.46). The average length of HU treatment was 31.7 months. Patients undergoing chronic transfusion therapy and those with active infection or inflammatory diseases were excluded from the study.

This research protocol received approval from the Institutional Review Board of São Rafael Hospital (protocol number: 1.400.527) and was conducted in compliance with the Declaration of Helsinki (1964) and its revisions. All individuals or their legal guardians provided a signed term of informed consent prior to enrollment in the study.

Laboratory Parameters

Blood samples were collected by venipuncture in the morning, after 12h of fasting, under standardized conditions. Analyses were performed at the Clinical and Toxicological Analysis Laboratory (LACTFAR) and the Anemia Research Laboratory (LPA), both affiliated with the Pharmaceutical School of the Federal University of Bahia (FACFAR-UFBA), as well as at the Laboratory of Investigation in Genetics and Translational Hematology, Gonçalo Moniz Institute (LIGHT-IGM).

Hematological parameters were evaluated using a Beckman Coulter LH 780 Hematology Analyzer (Beckman Coulter, Brea, California, USA). Qualitative and quantitative profiles of hemoglobin were assessed by high-performance liquid chromatography using an HPLC/Variant II hemoglobin testing system (BIO-RAD, Hercules, CA, USA). Biochemical parameters, as lipid profile, total proteins and fractions, total bilirubin and fractions, lactate dehydrogenase (LDH), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl-transferase (GGT), as well as renal profile and serum iron levels, were assessed using an A25 spectrophotometer autoanalyzer (Biosystems SA, Barcelona, Spain). Alpha-1 antitrypsin (AAT) and C-reactive protein (C-RP) levels were quantified using an Immage 800 system (Beckman Coulter, Fullerton, CA, USA). Serum ferritin was assessed on an Access 2 Immunoassay System (Beckman Coulter, Fullerton, CA, USA).

Molecular Analysis

Molecular analyses were carried out on genomic DNA obtained from whole blood samples. In overall, *CYP3A4* -392A>G (rs2740574), *CYP2D6* 1934G>A (rs3892097), *CAT* -21A>T (rs7943316), and -262C>T (rs1001179) variants were investigated using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique (Maruf et al., 2012; Sayed and Imam, 2012; Liu et al., 2015). Primers and restriction enzymes used in the PCR-RFLP reactions are presented in **Table S1**. The *SLC14A1* G>A (rs2298720) variant was investigated using the TaqMan method in accordance with the manufacturer's instructions. We also investigated beta S (β^S) haplotypes and alpha (α)-thalassemia-2 with the 3.7kb deletion (α^2 del 3.7kb thalassemia) since they are associated with alterations in the laboratory parameters of patients with SCA (Camilo-Araújo et al., 2014;

Darbari et al., 2014). Beta S haplotypes and α^2 del 3.7kb thalassemia were investigated by PCR-RFLP and allele-specific PCR, respectively (Sutton et al., 1989; Chong et al., 2000).

Statistical Analysis

All statistical analyses were performed using GraphPad Prism 6.0 and SPSS 17.0, with $p < 0.05$ considered statistically significant. The Shapiro-Wilk test was used to determine quantitative variable distributions. Mean values between two groups were compared using the unpaired t-test for variables with a normal distribution, while the Mann-Whitney *U* test was used for variables with non-normal distributions. ANOVA or Kruskal Wallis were used to compare mean values between more than two groups according to distribution. Frequencies of qualitative variables were also calculated. The Chi-square test (χ^2 -test) with Yates correction and Fischer's Exact test were used to investigate differences in genotypic and allelic frequencies between the two groups. Associations between parameters and polymorphisms were evaluated using codominant (wild type vs heterozygote vs variant), dominant (wild type vs heterozygote/variant), and recessive genetic (wild type/heterozygote vs variant) models, and multivariate linear regression analysis was employed to investigate the influence of the investigated variants on laboratory parameters. Results were expressed as mean \pm standard deviation (SD), median (minimum-maximum), or number or frequency where appropriate.

RESULTS

Laboratory Parameters of Patients With or Without HU Treatment

The hematological and biochemical parameters of patients receiving, or not, HU treatment are presented in **Table S2**. HU treatment was associated with an increase in HbF levels and, consequently, a reduction in HbS levels ($p < 0.05$). The analysis of biomarkers related to hemolysis and hepatic injury demonstrated an association between HU treatment and increases in hemoglobin, hematocrit, MCV and MCH, as well as reductions in reticulocytes, mean corpuscular hemoglobin concentration (MCHC), red blood cell distribution width (RDW), total bilirubin, AST, and LDH ($p < 0.05$). Regarding leukocyte and platelet profiles, decreased counts of WBC, neutrophils, eosinophils, lymphocytes, monocytes, platelets, as well as reduction in plateletcrit levels ($p < 0.05$) were seen in patients undergoing HU treatment compared to those who were not. HU was also significantly associated with increased high-density lipoprotein cholesterol (HDL-C) levels.

Frequencies of Investigated Polymorphisms in Patients With or Without HU Treatment

The analysis of genotypic and allelic distributions of the investigated polymorphisms revealed a lower frequency of the *CYP2D6* 1934GA+AA genotype in patients undergoing HU treatment compared to those who were not ($p = 0.0149$).

Moreover, lower and higher frequencies of the *CYP3A4* -392G ($p = 0.0248$) and *CAT* -21T ($p = 0.0485$) variant alleles were respectively observed in patients on HU compared to those who did not receive this treatment (Table S3). The rs7943316, rs1001179 and rs2298720 variants were found to be in Hardy-Weinberg Equilibrium (HWE), while rs3892097 and rs2740574 variants were not. The genotypic distribution of β^S haplotypes and α -thalassemia according to HU treatment are presented in Table S4; no significant differences were observed between the two groups ($p > 0.05$).

Associations Between Polymorphisms and Laboratory Parameters

Using a codominant genetic model, HU⁺ patients who had the *CYP2D6* heterozygote (1934GA) or variant (1934AA) genotypes presented significantly increased MCV, MCH and iron serum, as well as reduced total cholesterol, low-density lipoprotein cholesterol (LDL-C), uric acid, and alkaline phosphatase (ALP) compared with carriers of the wild type (1934GG) genotype. Furthermore, SCA HU⁺ patients who were carriers of the heterozygote genotype, *CYP2D6* 1934GA, presented intermediary values in laboratory investigations compared with carriers of the *CYP2D6* wild type (1934GG) and variant (1934AA) genotypes (Figure 1). Using a dominant genetic model for analysis in HU⁺ patients, associations between *CYP2D6* 1934G>A and significantly increased MCV, MCH, iron serum, and ALT were observed, in addition to significant decreases in total cholesterol, uric acid, ALP, total protein and globulin (Figure 2). *CAT* -21A>T demonstrated a significant association with reduced AAT concentrations under both co-dominant and recessive genetic models, while *CAT* -262C>T was found to be significantly associated with reduced lymphocyte counts in HU⁺ patients (Figure 3). HU⁺ patients who were carriers of heterozygote and


variant genotypes of both *CAT* -21A>T and -262C>T presented reductions in lymphocyte and platelet counts compared to carriers of the wild type genotypes of both polymorphisms (Figure 4). Finally, the *SLC14A1* G>A (rs2298720) was found to be significantly associated with elevated creatinine and reduced AAT in HU⁺ patients (Figure 5). None of these associations was detected in patients who did not receive HU. Moreover, *CYP3A4* -392A>G was not found to be clinically significant with respect to the parameters investigated.


Multivariate Linear Regression Analyses

Based on the findings of our association analyses among HU⁺ patients, multivariate linear regression analyses were conducted, including β^S haplotypes and α -thalassemia, as well as some laboratory parameters as confounding variables. Our analysis using the dominant genetic model revealed independent associations between the *CYP2D6* 1934G>A variant and increases in MCV, MCH, and iron serum levels, as well as decreases in total cholesterol, uric acid, total protein and globulin levels. We also observed an independent association between the *CAT* -21A>T variant and AAT using the recessive genetic model. All statistically significant results from our regression analyses are presented in Table 1.

DISCUSSION

The present study investigated the possible influence of variants in genes encoding DME and solute carrier on SCA patients' response to HU treatment. As expected, in contrast to SCA patients who did not receive HU, those who received this treatment presented increased HbF levels and improvements in hemolytic, hepatic and inflammatory profiles (hemoglobin, hematocrit, MCV, MCH,





reticulocytes, MCHC, RDW, AST, total bilirubin, LDH, WBC, neutrophils, eosinophils, lymphocytes, monocytes, platelets, and plateletcrit). These findings corroborate previous studies, which also demonstrated improvements in hemolytic, hepatic and inflammatory profiles in patients with SCA undergoing HU therapy (de Souza Santos and Maia, 2010; Voskaridou et al., 2010; de Souza Torres et al., 2012; Pallis et al., 2014; Belini Junior et al., 2015; Shome et al., 2016; Quarmyne et al., 2017; Colombatti et al., 2018). We further observed an increase in HDL-C concentration, demonstrating the effect of HU on lipid metabolism, which is consistent with our previous results (Yahouédéhou et al., 2018b; Yahouédéhou et al., 2019).

The present analysis of genotype and/or allele distribution of rs2740574, rs3892097, and rs7943316 revealed frequencies divergent to those observed in other studies conducted in different patient populations, as well as healthy controls (Maruf et al., 2012; Sayed and Imam, 2012; Liu et al., 2015). Contrarily, the frequencies of the rs1001179 and rs2298720 observed herein corroborate previously published results (Angona et al., 2013; Liu et al., 2015). Furthermore, we found a significantly reduced frequency of the *CYP2D6* 1934GA+AA genotype in patients receiving HU compared to those who did not, as well as significantly lower and higher frequencies of the *CYP3A4* -392G and *CAT* -21T allelic variants, respectively, in patients on HU versus those who did not receive this treatment.

Association analyses of polymorphisms with laboratory parameters revealed interesting results. SCA patients who were carriers of the variant (AA) genotype presented more pronounced alterations in response to HU treatment compared to those with the wild type (GG) genotype, indicating an association between the *CYP2D6* 1934G>A and an improvement in HU effects, that might be correlated with the number of variant A allele carried. Indeed, patients with the heterozygote (GA) genotype presented intermediary values on laboratory parameters compared to those with the wild type (GG) or homozygote variant (AA) genotypes. Reports have shown that the variant A allele leads to the incorrect splicing of mRNA, the formation of trunked protein, the reduction in enzymatic activity and a poor metabolism in patients with the variant (AA) genotype (Sayed and Imam, 2012). Hence, our findings suggest that this isoenzyme may inactivate HU or accelerate its elimination, which could explain the lessened effects in response to HU seen in rapid metabolizers (i.e., carriers of wild type GG genotype). Furthermore, in comparison to carriers of the wild type (GG) genotype, we observed that 95.65% of patients who received HU and were carriers of the heterozygote (GA) or variant (AA) genotypes presented MCV>98fL. This further reinforces the association between the variant A allele and improvements in HU effects, as report showed positive correlation between MCV and HbF levels and,




FIGURE 3 | Frequencies of *CAT* -21A>T (A, C) and -262C>T (E) and respective associations with laboratory parameters, using co-dominant (B, F), and recessive (D) models. The co-dominant genetic model compared three genotype groups (wild type vs heterozygote vs variant), while the recessive genetic model compared two genotype groups (wild type/heterozygote vs variant). AAT, alpha 1-antitrypsin; ANOVA, Kruskal-Wallis; unpaired t-test or Mann-Whitney *U* test where appropriate.

consequently, improved laboratory and clinical profiles (Borba et al., 2003).

Studies have demonstrated that HU is metabolized by catalase and that the rs7943316 and rs1001179 variants are associated with a reduction in or the absence of enzyme production (Huang et al., 2004; Juul et al., 2010; Liu et al., 2015). The present study observed associations between the *CAT*-21TT and *CAT*-262CT genotypes in patients receiving HU with respect to reductions in inflammatory biomarkers, such as AAT levels and lymphocyte counts. In addition, carriers of heterozygote and variant genotypes of both *CAT* -21A>T and -262C>T also exhibited significant reductions in lymphocyte and platelet counts compared to carriers of the wild type genotypes of both polymorphisms. These reductions in both lymphocytes and AAT, specifically in those who were carriers of variant alleles, may be due to the positive correlation, which exists between these inflammatory biomarkers in individuals undergoing HU therapy. Moreover, studies have demonstrated that levels of AAT, known as an acute-phase protein with anti-inflammatory properties, can decrease during HU therapy, either as a

consequence or a cause of reductions in WBC counts (Pallis et al., 2014; Yahouédéhou et al., 2019). Hence, our findings suggest the likelihood that lower catalase expression and activity may lead to higher HU bioavailability, which could explain the associations seen herein between the *CAT* -21A>T and -262C>T and improvement in inflammatory biomarkers.

Regarding the UTB, a recent study demonstrated a correlation between the upregulation of *SCL14A1* and higher *HBG2* expression in erythroid cells treated with HU (Walker and Ofori-Acquah, 2017). Another study involving patients with SCA reported an association between the polymorphism rs2298720 and alterations in HU pharmacokinetic parameters (Ware et al., 2011). In the present study, we found an association between the variant A allele of the polymorphism rs2298720 and elevated creatinine and reduced AAT concentrations in patients undergoing HU treatment. This results corroborate our previous findings, which observed a negative correlation between AAT and creatinine in patients with sickle cell disease, i.e., with HbSS, HbSC, or HbSβ⁺ (Carvalho et al., 2017). Moreover, it was reported that the accumulation of urea, an HU analog,




FIGURE 4 | Number of sickle cell anemia (SCA) patients receiving hydroxyurea (HU) who carry either two wild type or two variant alleles in both the *CAT* -21A>T and -262C>T variants **(A)** and association of the *CAT* haplotype with laboratory parameters **(B, C)**. CAT 0: patients with both *CAT* -21AA and -262CC genotypes, CAT 1: patients with both *CAT* -21AA+TT and -262CT genotypes, unpaired t-test or Mann Whitney *U* test where appropriate.




FIGURE 5 | Frequency of *SLC14A1* G>A (rs2298720) in patients with sickle cell anemia (SCA) undergoing hydroxyurea (HU) therapy **(A)** and its association with laboratory parameters under dominant genetic model analysis **(B, C)**. Two genotype groups (wild type vs heterozygote/variant) were compared. AAT, alpha 1-antitrypsin; unpaired t-test or Mann Whitney *U* test where appropriate.

might occur in human urothelial cells due to low *SLC14A1* expression (Hou et al., 2017). Considering these findings together, it is possible to speculate that the polymorphism rs2298720 may also be associated with diminished HU elimination, resulting in increased bioavailability. Moreover, as a result of reduced AAT concentrations, HU treatment may lead to an increase in creatinine serum levels, suggesting the beneficial effect of the variant A allele on inflammatory and renal dysfunction biomarkers.

The results of the multivariate regression analyses, which were performed using β^S haplotypes and α -thalassemia, as well as some laboratory biomarkers as confounding variables, confirmed the independent association of *CYP2D6* 1934G>A, *CAT* -21A>T, and -262C>T with several of these parameters. Accordingly, it will be interesting to investigate, in patients receiving HU who are carriers

of these variant alleles, the clinical repercussions of the presently observed alterations in laboratory parameters.

CONCLUSION

The present study investigated the effects of specific variants in genes encoding DME and solute carriers on SCA patients' response to HU treatment. Our results indicate that the *CYP2D6* (rs3892097), *CAT* (rs7943316 and rs1001179), and *SLC14A1* (rs2298720) variants are associated with HU efficacy, based on the laboratory parameters performed. Accordingly, we suggest that these variants are linked to the reduced metabolism or elimination of HU, which may increase its therapeutic effects in patients with SCA. Future investigation of this hypothesis might be the stepping-stone for a better

TABLE 1 | Multivariate linear regression models of *CYP2D6* 1934G>A and *CAT* -21A>T and -262C>T variants in patients with sickle cell anemia (SCA) undergoing hydroxyurea (HU) treatment.

| Dependent variables | Independent variables | β | R | p1 | p2 |
|---------------------------------|-----------------------|---------|------|--------------|--------------|
| CYP2D6 1934G>A MCV, fL | <i>CYP2D6</i> * | 0.42 | 0.54 | 0.006 | 0.008 |
| | HAP | 0.09 | | 0.544 | |
| | Tal | -0.34 | | 0.031 | |
| MCH, pg | <i>CYP2D6</i> * | 0.41 | 0.57 | 0.006 | 0.004 |
| | HAP | 0.13 | | 0.364 | |
| | Tal | -0.40 | | 0.010 | |
| Total cholesterol, mg/dL | <i>CYP2D6</i> * | -0.33 | 0.53 | 0.028 | 0.008 |
| | HAP | -0.04 | | 0.788 | |
| | Tal | 0.42 | | 0.008 | |
| Uric acid, mg/dL | <i>CYP2D6</i> * | -0.41 | 0.43 | 0.007 | 0.018 |
| | HAP | -0.10 | | 0.480 | |
| Iron serum, mcg/dL | <i>CYP2D6</i> * | 0.33 | 0.39 | 0.030 | 0.035 |
| | HAP | 0.20 | | 0.170 | |
| Total protein, g/dL | <i>CYP2D6</i> * | -0.32 | 0.44 | 0.032 | 0.013 |
| | HAP | -0.30 | | 0.044 | |
| Globulin, g/dL | <i>CYP2D6</i> * | -0.31 | 0.54 | 0.030 | 0.004 |
| | HAP | -0.38 | | 0.009 | |
| | Hemoglobin | -0.26 | | 0.066 | |
| CAT -21A>T AAT, mg/dL | CAT** | -0.39 | 0.40 | 0.011 | 0.035 |
| | HAPCAT | 0.51 | | 0.731 | |
| CAT -262C>T Lymphocytes, /mL | CAT* | -0.22 | 0.51 | 0.144 | 0.014 |
| | HAP | 0.34 | | 0.028 | |
| | Tal | -0.35 | | 0.026 | |

MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; HAP, β^S haplotype; Tal, α^2 del 3.7kb thalassemia; R, coefficient of determination; β , coefficient of regression; p1, p value of the independent variable; p2, p value of the model; *, dominant genetic model; **, recessive genetic model.

understanding of the HU metabolic pathway and to consider these variants as genetic markers of HU response.

DATA AVAILABILITY STATEMENT

All datasets presented in this study are included in the article/**Supplementary Material**.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional Review Board of the São Rafael

REFERENCES

- Angona, A., Bellosillo, B., Alvarez-Larrán, A., Martínez-Avilés, L., Camacho, L., Pairet, S., et al. (2013). Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide. *Leuk. Res.* 37, 917–921. doi: 10.1016/j.leukres.2013.03.013
- Babusikova, E., Jesenak, M., Evinova, A., Banovcin, P., and Dobrota, D. (2013). Frecuencia del polimorfismo -262 C/T en el gen de la catalasa y lesión oxidativa en niños eslovacos con asma bronquial. *Archiv. Bronconeumol.* 49, 507–512. doi: 10.1016/j.arbres.2013.04.002

Hospital. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

SY, EA, and MG conceived and designed the experiments. SY, JN, CG, SC, RS, CVBF, LF, UN, and RO collected the samples. SY, JN, CG, SC, RS, CVBF, LF, CAF, CA, and TR performed the experiments. SY and JN analyzed the data. VN and LR followed the patients. SY drafted the manuscript. JN and CG contributed to the writing of the manuscript. EA and MG supervised the study and critically revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (470959/2014-2 and 405595/2016-6) (MG), Programa Inova Fiocruz - Edital Geração de Conhecimento (VPPCB-007-FIO-18-2-66) (MG) and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001 (SY, SC, and RS). The sponsors of this study are public or nonprofit organizations that support science in general.

ACKNOWLEDGMENTS

The authors would like to thank all of the children and their legal guardians for their kind participation in the present study, as well as all personnel at the outpatient service of the Fundação de Hematologia e Hemoterapia da Bahia (HEMOBA), and all personnel of the Departamento de Toxicologia e Análises Clínicas, Faculdade de Farmácia (LACTFAR-UFBA). We would also like to thank Andris K. Walter for his critical analysis and English revision of the final manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2020.553064/full#supplementary-material>

- Bandeira, F. M. G. C., Peres, J. C., Carvalho, E. J., Bezerra, I., Araújo, A. S., Mello, M. R. B., et al. (2004). Hidroxiuréia em pacientes com síndromes falciformes acompanhados no Hospital Hemope, Recife, Brasil. *Rev. Bras. Hematol. Hemoter.* 26, 189–194. doi: 10.1590/S1516-84842004000300008
- Belini Junior, E., Silva, D. G. H., de Souza Torres, L., Okumura, J. V., de Castro Lobo, C. L., and Bonini-Domingos, C. R. (2015). Severity of Brazilian sickle cell disease patients: Severity scores and feasibility of the Bayesian network model use. *Blood Cells Mol. Dis.* 54, 321–327. doi: 10.1016/j.bcmd.2015.01.011
- Bhatnagar, V., Garcia, E. P., O'Connor, D. T., Brophy, V. H., Alcaraz, J., Richard, E., et al. (2010). CYP3A4 and CYP3A5 Polymorphisms and Blood Pressure

- Response to Amlodipine among African-American Men and Women with Early Hypertensive Renal Disease. *Am. J. Nephrol.* 31, 95–103. doi: 10.1159/000258688
- Borba, R., Lima, C. S. P., and Grotto, H. Z. W. (2003). Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy. *J. Clin. Lab. Anal.* 17, 66–72. doi: 10.1002/jcla.10070
- Božina, N., Bradamante, V., and Lovrić, M. (2009). Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk. *Arch. Ind. Hygiene Toxicol.* 60, 217–242. doi: 10.2478/10004-1254-60-2009-1885
- Camilo-Araújo, R. F., Amancio, O. M. S., Figueiredo, M. S., Cabanäs-Pedro, A. C., and Braga, J. A. P. (2014). Molecular analysis and association with clinical and laboratory manifestations in children with sickle cell anemia. *Rev. Bras. Hematol. Hemoter.* 36, 334–339. doi: 10.1016/j.bjhh.2014.06.002
- Carvalho, M. O. S., Souza, A. L. C. S., Carvalho, M. B., Pacheco, A. P. A. S., Rocha, L. C., do Nascimento, V. M. L., et al. (2017). Evaluation of Alpha-1 Antitrypsin Levels and SERPINA1 Gene Polymorphisms in Sickle Cell Disease. *Front. Immunol.* 8, 1491. doi: 10.3389/fimmu.2017.01491
- Chong, S. S., Boehm, C. D., Higgs, D. R., and Cutting, G. R. (2000). Single-tube multiplex-PCR screen for common deletion determinants of alpha-thalassemia. *Blood* 95, 360–362. doi: 10.1182/blood.V95.1.360
- Colombatti, R., Palazzi, G., Masera, N., Notarangelo, L. D., Bonetti, E., Samperi, P., et al. (2018). Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey. *Pediatr. Blood Cancer* 65, e26774. doi: 10.1002/pcb.26774
- Darbari, D. S., Nouraie, M., Taylor, J. G., Brugnara, C., Castro, O., and Ballas, S. K. (2014). Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia. *Eur. J. Haematol.* 92, 341–345. doi: 10.1111/ejh.12245
- de Souza Santos, F. K., and Maia, C. N. (2010). Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros. *Rev. Bras. Hematol. Hemoter.* 33, 105–109. doi: 10.5581/1516-8484.20110029
- de Souza Torres, L., da Silva, D. G. H., Junior, E. B., de Almeida, E. A., de Castro Lobo, C. L., Cançado, R. D., et al. (2012). The influence of hydroxyurea on oxidative stress in sickle cell anemia. *Rev. Bras. Hematol. Hemoter.* 34, 421–425. doi: 10.5581/1516-8484.20120106
- Ebbinghaus, D., Bánfi, G., Selinski, S., Blaszkewicz, M., Bürger, H., Hengstler, J. G., et al. (2017). Polymorphisms of xenobiotic metabolizing enzymes in bladder cancer patients of the Semmelweis University Budapest, Hungary. *J. Toxicol. Environ. Health Part A.* 80, 423–429. doi: 10.1080/10937404.2017.1304736
- Esteva-Font, C., Anderson, M. O., and Verkman, A. S. (2015). Urea transporter proteins as targets for small-molecule diuretics. *Nat. Rev. Nephrol.* 11, 113–123. doi: 10.1038/nrneph.2014.219
- Forsberg, L., Lyrenäs, L., Morgenstern, R., and de Faire, U. (2001). A common functional C-T substitution polymorphism in the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. *Free Radical Biol. Med.* 30, 500–505. doi: 10.1016/S0891-5849(00)00487-1
- García-Closas, M., Ye, Y., Rothman, N., Figueroa, J. D., Malats, N., Dinney, C. P., et al. (2011). A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. *Hum. Mol. Genet.* 20, 4282–4289. doi: 10.1093/hmg/ddr342
- Gravia, A., Chondrou, V., Sgourou, A., Papantoni, I., Borg, J., Katsila, T., et al. (2014). Individualizing fetal hemoglobin augmenting therapy for β -type hemoglobinopathies patients. *Pharmacogenomics* 15, 1355–1364. doi: 10.2217/pgs.14.101
- He, X.-F., Liu, Z.-Z., Xie, J.-J., Wang, W., Du, Y.-P., Chen, Y., et al. (2014). Association between the CYP3A4 and CYP3A5 polymorphisms and cancer risk: a meta-analysis and meta-regression. *Tumor Biol.* 35, 9859–9877. doi: 10.1007/s13277-014-2241-1
- Hou, R., Kong, X., Yang, B., Xie, Y., and Chen, G. (2017). SLC14A1: a novel target for human urothelial cancer. *Clin. Transl. Oncol.* 19, 1438–1446. doi: 10.1007/s12094-017-1693-3
- Huang, J., Kim-Shapiro, D. B., and King, S. B. (2004). Catalase-Mediated Nitric Oxide Formation from Hydroxyurea. *J. Med. Chem.* 47, 3495–3501. doi: 10.1021/jm030547z
- Huang, J., Yakubu, M., Kim-Shapiro, D. B., and King, S. B. (2006). Rat liver-mediated metabolism of hydroxyurea to nitric oxide. *Free Radical Biol. Med.* 40, 1675–1681. doi: 10.1016/j.freeradbiomed.2006.01.002
- Jin, M., Gock, S. B., Jannetto, P. J., Jentzen, J. M., and Wong, S. H. (2005). Pharmacogenomics as Molecular Autopsy for Forensic Toxicology: Genotyping Cytochrome P450 3A4*1B and 3A5*3 for 25 Fentanyl Cases. *J. Anal. Toxicol.* 29, 590–598. doi: 10.1093/jat/29.7.590
- Juul, T., Malolepszy, A., Dybkaer, K., Kidmose, R., Rasmussen, J. T., Andersen, G. R., et al. (2010). The in Vivo Toxicity of Hydroxyurea Depends on Its Direct Target Catalase. *J. Biol. Chem.* 285, 21411–21415. doi: 10.1074/jbc.M110.103564
- King, S. (2003). The Nitric Oxide Producing Reactions of Hydroxyurea. *CMC* 10, 437–452. doi: 10.2174/0929867033368213
- King, S. (2005). N-Hydroxyurea and Acyl Nitroso Compounds as Nitroxyl (HNO) and Nitric Oxide (NO) Donors. *CTMC* 5, 665–673. doi: 10.2174/1568026054679362
- Kolliopoulou, A., Stratopoulos, A., Siamoglou, S., Sgourou, A., Ali, B. R., Papachatzopoulou, A., et al. (2017). Key Pharmacogenomic Considerations for Sickle Cell Disease Patients. *OMICS: A J. Integr. Biol.* 21, 314–322. doi: 10.1089/omi.2017.0058
- Kovacic, P. (2011). Hydroxyurea (therapeutics and mechanism): Metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. *Med. Hypotheses* 76, 24–31. doi: 10.1016/j.mehy.2010.08.023
- Liu, Y., Xie, L., Zhao, J., Huang, X., Song, L., Luo, J., et al. (2015). Association between catalase gene polymorphisms and risk of chronic hepatitis B, hepatitis B virus-related liver cirrhosis and hepatocellular carcinoma in Guangxi population: a case-control study. *Med. (Baltimore)* 94, e702. doi: 10.1097/MD.0000000000000702
- Ma, Q., Wyszynski, D. F., Farrell, J. J., Kutlar, A., Farrer, L. A., Baldwin, C. T., et al. (2007). Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. *Pharmacogenom. J.* 7, 386–394. doi: 10.1038/sj.tpj.6500433
- Maruf, A., Ahmed, M., Azad, M. A. K., Ahmed, M., and Hasnat, A. (2012). CYP3A Genotypes in Bangladeshi Tuberculosis Patients. *Bangladesh Med. Res. Council Bull.* 38, 1–5. doi: 10.3329/bmrcb.v38i1.6978
- Matsuda, K., Takahashi, A., Middlebrooks, C. D., Obara, W., Nasu, Y., Inoue, K., et al. (2015). Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population. *Hum. Mol. Genet.* 24, 1177–1184. doi: 10.1093/hmg/ddu512
- Pallis, F. R., Conran, N., Fertrin, K. Y., Olalla Saad, S. T., Costa, F. F., and Franco-Penteado, C. F. (2014). Hydroxycarbamide reduces eosinophil adhesion and degranulation in sickle cell anaemia patients. *Br. J. Haematol.* 164, 286–295. doi: 10.1111/bjh.12628
- Perianayagam, M. C., Liangos, O., Kolyada, A. Y., Wald, R., MacKinnon, R. W., Li, L., et al. (2007). NADPH Oxidase p22phox and Catalase Gene Variants Are Associated with Biomarkers of Oxidative Stress and Adverse Outcomes in Acute Renal Failure. *JASN* 18, 255–263. doi: 10.1681/ASN.2006070806
- Quarmyne, M.-O., Dong, W., Theodore, R., Anand, S., Barry, V., Adisa, O., et al. (2017). Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort: Hydroxyurea Effectiveness in Sickle Cell Anemia. *Am. J. Hematol.* 92, 77–81. doi: 10.1002/ajh.24587
- Rafnar, T., Vermeulen, S. H., Sulem, P., Thorleifsson, G., Aben, K. K., Witjes, J. A., et al. (2011). European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. *Hum. Mol. Genet.* 20, 4268–4281. doi: 10.1093/hmg/ddr303
- Rees, D. C., Williams, T. N., and Gladwin, M. T. (2010). Sickle-cell disease. *Lancet* 376, 2018–2031. doi: 10.1016/S0140-6736(10)61029-X
- Sands, J. M. (2002). Molecular Approaches to Urea Transporters. *J. Am. Soc. Nephrol.* 13, 2795–2806. doi: 10.1097/01.ASN.0000035084.94743.7C
- Sassi, H., Bachir, D., Habibi, A., Astier, A., Galactéros, F., and Hulin, A. (2010). No effect of CYP450 and P-glycoprotein on hydroxyurea in vitro metabolism. *Fundam. Clin. Pharmacol.* 24, 83–90. doi: 10.1111/j.1472-8206.2009.00723.x
- Sayed, S. K., and Imam, H. M. K. (2012). Study of the Association of CYP2D6*4 Polymorphism with the Susceptibility of HCV- Related Liver Cirrhosis and Liver Cancer. *Life Sci. J.* 9, 1571–1577. doi: 10.7537/marslsj090312.228
- Sheng, Y.-J., Wu, G., He, H.-Y., Chen, W., Zou, Y.-S., Li, Q., et al. (2014). The association between CYP2E1 polymorphisms and hepatotoxicity due to anti-tuberculosis drugs: A meta-analysis. *Infection Genet. Evol.* 24, 34–40. doi: 10.1016/j.meegid.2014.01.034
- Shome, D. K., Al Ajmi, A., Radhi, A. A., Mansoor, E. J., and Majed, K. S. (2016). The Effect of Hydroxyurea Therapy in Bahraini Sickle Cell Disease Patients. *Indian J. Hematol. Blood Transf.* 32, 104–109. doi: 10.1007/s12288-015-0529-y
- Silva-Pinto, A. C., Angulo, I. L., Brunetta, D. M., Neves, F. I. I., Bassi, S. C., Santis, G. C. D., et al. (2013). Clinical and hematological effects of hydroxyurea

- therapy in sickle cell patients: a single-center experience in Brazil. *Sao Paulo Med. J.* 131, 238–243. doi: 10.1590/1516-3180.2013.1314467
- Stewart, G. (2011). The emerging physiological roles of the SLC14A family of urea transporters: Facilitative urea transporters. *Br. J. Pharmacol.* 164, 1780–1792. doi: 10.1111/j.1476-5381.2011.01377.x
- Sutton, M., Bouhassira, E. E., and Nagel, R. L. (1989). Polymerase chain reaction amplification applied to the determination of β -like globin gene cluster haplotypes. *Am. J. Hematol.* 32, 66–69. doi: 10.1002/ajh.2830320113
- Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., et al. (2010). The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). *Blood* 115, 2354–2363. doi: 10.1182/blood-2009-05-221333
- Walker, A. L., and Ofori-Acquah, S. F. (2017). Sustained enhancement of OCTN1 transporter expression in association with hydroxyurea induced γ -globin expression in erythroid progenitors. *Exp. Hematol.* 45, 69–73.e2. doi: 10.1016/j.exphem.2016.09.001
- Ware, R. E., Eggleston, B., Redding-Lallinger, R., Wang, W. C., Smith-Whitley, K., Daeschner, C., et al. (2002). Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. *Blood* 99, 10–14. doi: 10.1182/blood.V99.1.10
- Ware, R. E., Despotovic, J. M., Mortier, N. A., Flanagan, J. M., He, J., Smeltzer, M. P., et al. (2011). Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. *Blood* 118, 4985–4991. doi: 10.1182/blood-2011-07-364190
- Ware, R. E. (2010). How I use hydroxyurea to treat young patients with sickle cell anemia. *Blood* 115, 5300–5311. doi: 10.1182/blood-2009-04-146852
- Yahouédéhou, S. C. M. A., Adorno, E. V., da Guarda, C. C., Ndidi, U. S., Carvalho, S. P., Santiago, R. P., et al. (2018a). Hydroxyurea in the management of sickle cell disease: pharmacogenomics and enzymatic metabolism. *Pharmacogenom. J.* 18, 730–739. doi: 10.1038/s41397-018-0045-1
- Yahouédéhou, S. C. M. A., Carvalho, M. O. S., Oliveira, R. M., Santiago, R. P., da Guarda, C. C., Carvalho, S. P., et al. (2018b). Sickle Cell Anemia Patients in Use of Hydroxyurea: Association between Polymorphisms in Genes Encoding Metabolizing Drug Enzymes and Laboratory Parameters. *Dis. Markers* 2018, 1–11. doi: 10.1155/2018/6105691
- Yahouédéhou, S. C. M. A., da Guarda, C. C., Figueiredo, C. V. B., Santiago, R. P., Carvalho, S. P., Fiuza, L. M., et al. (2019). Hydroxyurea alters hematological, biochemical and inflammatory biomarkers in Brazilian children with SCA: Investigating associations with β S haplotype and α -thalassemia. *PLoS One* 14, e0218040. doi: 10.1371/journal.pone.0218040

Conflict of Interest: The authors declare that our research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Yahouédéhou, Neres, da Guarda, Carvalho, Santiago, Figueiredo, Fiuza, Ndidi, de Oliveira, Fonseca, Nascimento, Rocha, Adanho, da Rocha, Adorno and Goncalves. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.